Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate

• Published in: Modern rheumatology Vol. 25; no. 2; pp. 251 - 256
• Main Authors: Kobayakawa, Tomonori, Kojima, Toshihisa, Takahashi, Nobunori, Hayashi, Masatoshi, Yabe, Yuichiro, Kaneko, Atsushi, Shioura, Tomone, Saito, Kiwamu, Hirano, Yuji, Kanayama, Yasuhide, Miyake, Hiroyuki, Asai, Nobuyuki, Funahashi, Koji, Hirabara, Shinya, Hanabayashi, Masahiro, Asai, Shuji, Ishiguro, Naoki
• Format: Journal Article
• Language: English
• Published: United States Informa Healthcare 01.03.2015; Taylor & Francis
• Subjects: Adult; Aged; Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - drug therapy; Biological Products - therapeutic use; Cancer; Drug Substitution; Drug Therapy, Combination; Female; Humans; Japan; Male; Medical treatment; Methotrexate; Methotrexate - therapeutic use; Middle Aged; Prescription drugs; Rheumatoid arthritis; Second-line drug; Switching; TNF inhibitor; Tocilizumab; Treatment Outcome; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Tumors; Japan; Second-line drug; Methotrexate; TNF inhibitor; Tocilizumab; Rheumatoid arthritis

Abstract Objectives. The purpose of this study was to explore drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors (TNFi) in clinical practice in patients with rheumatoid arthritis (RA) on low-dose methotrexate (MTX) or without MTX. Methods. A total of...